Day: November 24, 2025

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief Executive’s Annual General Meeting (AGM) address. For the quarter ending December 31, 2025, management expects gross revenue of more than US$30.0 million from sales of Ryoncil® (remestemcel-L-rknd). This represents more than 37% increase on the US$21.9 million in gross revenue from Ryoncil® in the prior quarter ended September 30, 2025. About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary...

New York, NY, Nov. 24, 2025 (GLOBE NEWSWIRE) — Invest Green Acquisition Corporation (the “Company”) announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit on November 24, 2025. The units are expected to be listed for trading on the Nasdaq Global Market under the ticker symbol “IGACU” beginning November 25, 2025. Each unit consists of one Class A ordinary share and one right to receive one tenth of a Class A ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the Company expects that its Class A ordinary shares and rights will be listed on the Nasdaq Global Market under the symbols “IGAC” and “IGACR,” respectively. The offering is expected to close on November 26, 2025, subject to customary closing...

CALGARY, Alberta, Nov. 24, 2025 (GLOBE NEWSWIRE) — Maxim Power Corp. (“MAXIM” or the “Corporation”) (TSX: MXG) announced today that it has successfully settled a portion of its previously disclosed claim for compensation against third-parties in relation to the non-injury fire on September 30, 2022, which caused damage to Milner 2’s (“M2”) air inlet filter house (the “Claim”). The Claim was filed in 2024 against multiple third parties and this settlement is with one of those parties. MAXIM’s portion of the settlement, net of fees, is approximately $6.5 million. The amount represents the maximum net amount available from the insurance policy of the third party who has agreed to settle. MAXIM anticipates receipt of the settlement proceeds in the fourth quarter of 2025. In addition, MAXIM continues to pursue...

PERTH, Western Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) — Alkane Resources Limited (ASX: ALK; TSX: ALK; OTCQX: ALKEF) (‘Alkane’ or ‘the Company’) is pleased to announce the appointment of Ms Denise McComish to the Alkane Board as an independent Non-Executive Director with effect from 1 December 2025. Ms McComish will also serve as Chair of Alkane’s Audit & Risk Committee. Ms McComish has extensive financial, strategy, corporate, ESG and board experience across multiple sectors. She was a partner with KPMG for 30 years, specialising in audit and advisory services, and served as a National Board Member and National Mining Leader. Ms McComish is currently a Non-Executive Director of Web Travel Group Limited, WA Electricity Generation and Retail Corporation (Synergy) and for purpose organisation Beyond Blue Limited. She served...

Vancouver, BC, Nov. 24, 2025 (GLOBE NEWSWIRE) — Trident Resources Corp. (TSX-V: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company”) is pleased to announce the Company has entered into an agreement dated November 24, 2025 (the “Agreement”) with i2i Marketing Group, LLC (“i2i“) of Key West Florida, USA, whereby i2i will provide marketing and media distribution for an initial term of six (6) months commencing on November 24th, 2025. An initial fee of US$250,000 is payable. Thereafter, the marketing agreement may continue on a month-to-month basis with supplemental expenditures agreed to by the parties for the services being rendered. i2i will create an advertising campaign and utilize its physical marketing program strategy with the aim of increasing investor awareness through various on-line platforms and methods of engagement,...

Ad hoc announcement pursuant to Art. 53 LRItvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studies One-time dose of Itvisma replaces SMN1 gene, potentially reducing the need for chronic SMA treatment Gene replacement therapy now available to eligible people of all ages living with SMABasel, November 24, 2025 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Itvisma® (onasemnogene abeparvovec-brve) for the treatment of children two years and older, teens and adults living with spinal muscular atrophy (SMA) with a confirmed mutation in the survival motor neuron 1 (SMN1) gene, making it the first and only gene replacement therapy available for this broad population. Itvisma is uniquely designed...

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Hall Chadwick Acquisition Corp. (NASDAQ:HCACU) (the “Company”) announced the closing of its initial public offering of 20,700,000 units, which includes 2,700,000 units issued pursuant to the exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $207,000,000. The Company’s units began trading on the Nasdaq Global Market (“Nasdaq”) on November 21, 2025, under the ticker symbol “HCACU.” Each unit consists of one Class A ordinary share of the Company and one right to receive one tenth (1/10) of a Class A ordinary share upon the consummation of the Company’s initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights will be listed on Nasdaq...